Human FGF-21 is a substrate of fibroblast activation protein

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Coppage, Andrew L ^a   Heard, Kathryn R ^a,b   Dimare, Matthew T ^a,b   Liu, Yuxin ^a,b   Wu, Wengen ^a,b   Lai, Jack H ^a,b   Bachovchin, William W ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Arisaph Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARI 3099; FIBROBLAST ACTIVATION PROTEIN; FIBROBLAST GROWTH FACTOR 21; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; GELATINASE; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; SEPRASE; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HALF LIFE TIME; HUMAN; MACACA FASCICULARIS; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMA; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; SPECIES DIFFERENCE;

ANIMALS; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; GELATINASES; HUMANS; MACACA FASCICULARIS; MEMBRANE PROTEINS; MICE; PROTEOLYSIS; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; SPECIES SPECIFICITY;

EID: 84962516266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151269     Document Type: Article

References (33)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005 Jun; 115(6):1627-35. PMID: 15902306
2. Long YC, Kharitonenkov A. Hormone-like fibroblast growth factors and metabolic regulation. Biochim Biophys Acta. 2011 Jul; 1812(7):791-5. doi: 10.1016/j.bbadis.2011.04.002 PMID: 21504790
3. Popovici C, Roubin R, Coulier F, Birnbaum D. An evolutionary history of the FGFsuperfamily. Bioessays. 2005 Aug; 27(8):849-57. PMID: 16015590
4. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009 Nov; 150(11):4931-40. doi: 10.1210/en. 2009-0532 PMID: 19819944
5. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology. 2009 Oct; 150(10):4625-33. doi: 10.1210/en. 2009-0119 PMID: 19589869
6. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab. 2009 Nov; 297(5):E1105-14. doi: 10.1152/ajpendo.00348.2009 PMID: 19706786
7. Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology. 2013 Sep; 154(9):3366-76. doi: 10.1210/en. 2012-2276 PMID: 23825123
8. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, Hager T, et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology. 2012 Sep; 153(9):4192-203. doi: 10.1210/en. 2012-1211 PMID: 22798348
9. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007 Feb; 148(2):774-81. PMID: 17068132
10. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21(FGF21)-resistant state. Diabetes. 2010 Nov; 59(11):2781-9. doi: 10.2337/db10-0193 PMID: 20682689
11. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013 Sep. 3;18(3):333-40. doi: 10. 1016/j.cmet.2013.08.005 PMID: 24011069
12. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, Micanovic R, et al. Fundamentals of FGF19&FGF21 action in vitro and in vivo. PLoSOne. 2012;7(5):e38438. doi: 10.1371/journal.pone. 0038438 PMID: 22675463
13. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008 May; 57(5):1246-53. doi: 10.2337/db07-1476 PMID: 18252893
14. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000 Jun. 21;1492(1):203-6. PMID: 10858549
15. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007 May; 27(9):3417-28. PMID: 17339340
16. Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem. 2011 Oct. 7;286(40):34533-41. doi: 10.1074/jbc. M111.248591 PMID: 21846717
17. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, Sandusky GE, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006 Sep; 55(9):2470-8. PMID: 16936195
18. Zhang Y, Xie Y, Berglund ED, Coate KC, He TT, Katafuchi T, et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife. 2012;1:e00065. doi: 10.7554/eLife.00065 PMID: 23066506
19. Zhang Y, Lei T, Huang JF, Wang SB, Zhou LL, Yang ZQ, et al. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol. 2011 Aug. 6;342(1-2):41-7. doi: 10.1016/j.mce.2011.05.003 PMID: 21664250
20. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009 Jan; 58(1):250-9. doi: 10.2337/db08-0392 PMID: 18840786
21. Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, et al. Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes. PLoSOne. 2012;7(11):e49345. doi: 10.1371/journal.pone.0049345 PMID: 23209571
22. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, et al. Different roles of N- and C-termini in the functional activity of FGF21. J Cell Physiol. 2009 May; 219(2):227-34. doi: 10. 1002/jcp. 21675 PMID: 19117008
23. Huang CH, Suen CS, Lin CT, Chien CH, Lee HY, Chung KM, et al. Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J Biochem. 2011 Jun; 149(6):685-92. doi: 10.1093/jb/mvr017 PMID: 21288888
24. Jambunathan K, Watson DS, Endsley AN, Kodukula K, Galande AK. Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein alpha. FEBS Lett. 2012 Jul. 30;586(16):2507-12. doi: 10.1016/j.febslet.2012.06.015 PMID: 22750443
25. Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem. 2006 Mar. 17;281(11):7437-44. PMID: 16410248
26. Gorrell M, Sunmi S, Wang X, Novel Metabolic Disease Therapy. United States. 2012.
27. Poplawski SE, Lai JH, Li Y, Jin Z, Liu Y, Wu W, et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77. doi: 10.1021/jm400351a PMID: 23594271
28. Keane FM, Yao TW, Seelk S, Gall MG, Chowdhury S, Poplawski SE, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio. 2013;4:43-54. doi: 10.1016/j.fob.2013.12.001 PMID: 24371721
29. Stein S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care. 2009 Jan; 32(1):126-8. doi: 10.2337/dc08-1054 PMID: 18840768
30. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoSOne. 2013;8(3):e58575. doi: 10.1371/journal.pone.0058575 PMID: 23536797
31. Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N, et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 2009 Jan 5;583(1):19-24. doi: 10.1016/j. febslet.2008.11.023 PMID: 19059246
32. Zhen EY, Jin Z, Ackermann BL, Thomas MK, Gutierrez JA. Circulating FGF21 Proteolytic Processing Mediated by Fibroblast Activation Protein. Biochem J. 2015 Dec. 3.
33. Dunshee DR, Bainbridge TW, Kljavin NM, Zavala-Solorio J, Schroeder AC, Chan R, et al. Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21. J Biol Chem. 2016 Jan 21.